# US 2026/0184739 A1 · Method of purifying hemopexin using mixed-mode chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0184739 A1
- Document ID: US20260184739A1
- Status: Published application
- Kind: A1
- Application number: 19/130,479
- Filed: 2023-12-22
- Published: 2026-07-02
- Earliest claimed: 2022-12-22
- Assignees: CSL Behring GmbH
- Applicants: CSL Behring AG
- Inventors: Karl Beaumont MCCANN; Hal BRALEY; Chathuri WIJEKOON
- Web page: https://patentgrep.com/patent/US20260184739A1

## CPC

- C07K 1/18: Ion-exchange chromatography
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/1709: {from mammals}
- C07K 1/165: {mixed-mode chromatography}
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 1/36: by a combination of two or more processes of different types
- C07K 14/4717: {Plasma globulins, lactoglobulin}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein is a method of purifying proteins, in particular hemopexin, comprising passing a solution comprising hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The present disclosure also extends to compositions comprising purified hemopexin and uses thereof.

## Claims

### Claim 1

A method of purifying hemopexin from a solution containing hemopexin and other proteins, the method comprising:
(i) providing a solution comprising hemopexin and other proteins, wherein the solution comprises less than about 300 mM sodium chloride (NaCl);
(ii) passing the solution of step (i) through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin over binding of the other proteins to the resin;
(iii) washing the resin after step (ii) to remove unbound proteins;
(iv) eluting the hemopexin bound to the resin after step (iii); and
(v) recovering the hemopexin eluted in step (iv).

### Claim 2 (depends on 1)

The method of claim 1, wherein the mixed-mode cation exchange chromatography resin the structure of formula (I) or (II):

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the recovered hemopexin eluate of step (v) has a purity of at least about 50%.

### Claim 4 (depends on 3)

The method of claim 3, wherein the recovered hemopexin eluate of step (v) has a purity of from about 70% to about 99%.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the solution of step (i) has a pH of from about 6.2 to about 6.6.

### Claim 6 (depends on 5)

The method of claim 5, wherein the solution of step (i) has a pH of about 6.4.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the solution of step (i) comprises from about 160 mM to about 250 mM NaCl.

### Claim 8 (depends on 7)

The method of claim 7, wherein the solution of step (i) comprises from about 200 mM to about 250 mM NaCl.

### Claim 9 (depends on 8)

The method of claim 8, wherein the solution of step (i) comprises about 225 mM NaCl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the solution of step (i) comprises:
(a) a pH of from about 6.2 to about 6.6;
(b) from about 20 mM to about 60 mM phosphate buffer; and
(c) from about 160 mM to about 250 mM NaCl.

### Claim 11 (depends on 10)

The method of claim 10, wherein the solution of step (i) comprises:
(a) a pH of about 6.4;
(b) about 40 mM phosphate buffer; and
(c) about 225 mM NaCl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the amount of hemopexin that is passed through the resin in step (ii) is from about 1 mg to about 40 mg per mL of resin.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein the solution of step (i) has a conductivity of from about 23 mS/cm to about 28 mS/cm.

### Claim 14 (depends on 13)

The method of claim 13, wherein the solution of step (i) has a conductivity of from about 23 mS/cm to about 25 mS/cm.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14, wherein the solution is a human plasma fraction.

### Claim 16 (depends on 14)

The method of claim 14, wherein the solution of step (i) is derived from a Cohn Fraction IV.

### Claim 17 (depends on 16)

The method of claim 16, wherein the solution of step (i) is derived from a Cohn Fraction IV4.

### Claim 18 (depends on 16, 17)

The method of claim 16 or claim 17, wherein the solution of step (i) is prepared by (a) resuspending the Cohn Fraction IV in an extraction buffer to obtain a resuspended Cohn Fraction IV, (b) passing the resuspended Cohn Fraction IV of step (a) through a filter, and (c) recovering the filtered Cohn Fraction IV extract from step (b).

### Claim 19 (depends on 18)

The method of claim 18, wherein step (a) comprises resuspending the Cohn Fraction IV in an extraction buffer at a Cohn Fraction IV: extraction buffer ratio of from about 1:2 to about 1:20.

### Claim 20 (depends on 19)

The method of claim 19, wherein step (a) comprises resuspending the Cohn Fraction IV in an extraction buffer at a Cohn Fraction IV: extraction buffer ratio of about 1:2.5.

### Claim 21 (depends on 18, 19, 20)

The method of any one of claims 18 to 20, wherein the extraction buffer has a pH of from about 6 to about 8.

### Claim 22 (depends on 21)

The method of claim 21, wherein the extraction buffer has a pH of from about 6.2 to about 7.5.

### Claim 23 (depends on 22)

The method of claim 22, wherein the extraction buffer has a pH of about 7.5.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The method of any one of claims 18 to 23, wherein the extraction buffer comprises from about 20 mM to about 500 mM NaCl.

### Claim 25 (depends on 24)

The method of claim 24, wherein the extraction buffer comprises about 400 mM NaCl.

### Claim 26 (depends on 25)

The method of claim 25, wherein the extraction buffer comprises about 40 mM sodium phosphate and about 400 mM NaCl.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 18 to 26, wherein the filtered Cohn Fraction IV extract of step (c) is passed through a fine filter having a pore size of about 0.5 μm or less to obtain a clarified Cohn Fraction IV extract.

### Claim 28 (depends on 27)

The method of claim 27, wherein the pH of the clarified Cohn Fraction IV extract is adjusted to a value of from about 6.2 to about 6.6.

### Claim 29 (depends on 28)

The method of claim 28, wherein the pH of the clarified Cohn Fraction IV extract is adjusted to about 6.4.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27 to 29, wherein the conductivity of the clarified Cohn Fraction IV extract is adjusted to a value of from about 24 mS/cm to about 30 mS/cm.

### Claim 31 (depends on 30)

The method of claim 30, wherein the conductivity of the clarified Cohn Fraction IV extract is adjusted to a value of from about 26 mS/cm to about 28 mS/cm.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1 to 31, wherein the conductivity of the recovered hemopexin eluate of step (v) is from about 18 to about 19 mS/cm.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, further comprising:
(vi) passing the recovered hemopexin eluate of step (v) through a mixed-mode anion exchange chromatography resin under conditions that allow any impurities in the recovered hemopexin eluate to bind to the resin while allowing the hemopexin to pass through the resin as an unbound fraction; and
(vii) recovering the unbound fraction comprising hemopexin.

### Claim 34 (depends on 33)

The method of claim 33, wherein the mixed-mode anion exchange chromatography resin from step (vi) is equilibrated with a buffer comprising a pH of from about 7.0 to about 8.0.

### Claim 35 (depends on 33, 34)

The method of claim 33 or claim 34, wherein the equilibration buffer has a pH of about 7.5.

### Claim 36 (depends on 33, 34, 35)

The method of any one of claims 33 to 35, wherein the equilibration buffer comprises from about 100 mM to about 200 mM NaCl.

### Claim 37 (depends on 36)

The method of claim 36, wherein the equilibration buffer comprises about 150 mM NaCl.

### Claim 38 (depends on 33, 34, 35, 36, 37)

The method of any one of claims 33 to 37, further comprising exposing the recovered unbound fraction of step (vii) to a virus inactivation step to obtain a virus inactivated hemopexin solution.

### Claim 39 (depends on 38)

The method of claim 38, wherein the virus inactivation step comprises exposing the recovered unbound fraction of step (vii) to a solution comprising a surfactant and a solvent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the solvent is tri-n-butyl phosphate (TnBP).

### Claim 41 (depends on 39, 40)

The method of claim 39 or claim 40, wherein the surfactant is polysorbate 80 (PS80).

### Claim 42 (depends on 40, 41)

The method of claim 40 or claim 41, wherein the solvent detergent treatment comprises exposing the recovered unbound fraction of step (vii) to 1% polysorbate 80 (PS80) and 0.3% tri-n-butyl phosphate (TnBP).

### Claim 43 (depends on 38, 39, 40, 41, 42)

The method of any one of claims 38 to 42, further comprising:
(ix) passing the virus inactivated hemopexin solution through an ion exchange chromatography resin under conditions that allow the hemopexin to bind to the resin;
(x) optionally washing the resin following step (ix); and
(xi) eluting the hemopexin bound to the resin in step (ix); and
(xii) recovering the eluted hemopexin from step (xi).

### Claim 44 (depends on 43)

The method of claim 43, wherein the ion exchange chromatography resin is a cation exchange chromatography resin or an anion exchange chromatography resin.

### Claim 45 (depends on 43, 44)

The method of claim 43 or claim 44, wherein prior to step (ix), the pH of the virus inactivated hemopexin solution is adjusted to a value of from about 6.0 to about 6.2.

### Claim 46 (depends on 45)

The method of claim 45, wherein prior to step (ix), the pH of the virus inactivated hemopexin solution is adjusted to about 6.0.

### Claim 47 (depends on 43, 44, 45, 46)

The method of any one of claims 43 to 46, wherein prior to step (ix), the conductivity of the virus inactivated hemopexin solution is adjusted to a value of from about 8 mS/cm to about 12 mS/cm.

### Claim 48 (depends on 43, 44, 45, 46)

The method of any one of claims 43 to 46, wherein prior to step (ix), the conductivity of the virus inactivated hemopexin solution is adjusted to about 10 mS/cm.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The method of any one of claims 43 to 48, further comprising exposing the eluted hemopexin recovered in step (xii) to diafiltration to adjust the concentration of the eluted hemopexin to a value of from about 50 mg/mL to about 120 mg/mL.

### Claim 50 (depends on 49)

The method of claim 49, wherein the concentration of the eluted hemopexin is adjusted to about 100 mg/mL.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 1 to 50, wherein the recovered hemopexin is subjected to virus filtration.

### Claim 52 (depends on 51)

The method of claim 51, wherein the virus filtration comprises passing the recovered hemopexin through a virus filter having a pore size of from about 15 nm to about 20 nm diameter.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A composition comprising the hemopexin recovered by the method of any one of claims 1 to 52.

### Claim 54

A composition comprising a combination of any two or more of the characteristics selected from the group consisting of:
(a) a hemopexin content of from about 95 mg/mL to about 110 mg/mL;
(b) heme binding activity of from about 1000 μM to about 2000 μM;
(c) heme specific binding activity of at least about 80% of total protein
(d) a CD91 dissociation constant (KD) of from about 0.50 μM to about 2.0 μM;
(e) a transferrin content of less than about 0.50 mg/mL;
(f) an albumin content of less than about 0.05 mg/mL;
(g) a haptoglobin content of less than about 0.05 mg/ml;
(h) an Apo-A1 content of less than about 0.10 mg/mL;
(i) a high molecular weight (HMW) hemopexin aggregate content of less than about 1.0% of total protein, as determined by size exclusion-high-performance liquid chromatography;
(j) a hemopexin monomer content of at least about 90% of total protein, as determined by size exclusion-high-performance liquid chromatography;
(k) a low molecular weight (LMW) impurity content of less than about 1.0% of total protein, as determined by size exclusion-high-performance liquid chromatography;
(l) a hemopexin purity content of at least about 80% of total protein, as determined by reduced SDS-PAGE or as determined by non-reduced SDS-PAGE;
(m) an isoelectric point (pI) of from about 5.0 to about 6.5, as determined by Capillary isoelectric focusing (cIEF);
(n) a level of protease activity of less than about 5 nKat/L;
(o) a level of prekallikrein activity of less than about 30 IU/mL;
(p) a tri (n-butyl) phosphate (TnBP) content of less than about 10 μg/mL; and
(q) a PS80 content of less than about 20 mg/mL.

### Claim 55

A composition comprising a combination of any two or more of the characteristics selected from the group consisting of:
(a) a hemopexin content of from about 95 mg/mL to about 110 mg/mL;
(b) heme binding activity of from about 1600 μM to about 1800 μM;
(c) heme specific binding activity of at least about 97% of total protein;
(d) a CD91 dissociation constant (KD) of from about 1.10 μM to about 1.20 μM;
(e) a transferrin content of less than about 0.25 mg/ml;
(f) an albumin content of less than about 0.009 mg/mL;
(g) a haptoglobin content of less than about 0.03 mg/ml;
(h) an Apo-A1 content of less than about 0.06 mg/mL;
(i) a high molecular weight (HMW) hemopexin aggregate content of less than about 0.6% of total protein;
(j) a hemopexin monomer content of at least about 99% of total protein;
(k) a low molecular weight (LMW) impurity content of less than about 0.4% of total protein;
(l) a hemopexin purity content of at least about 88% of total protein;
(m) an isoelectric point (pI) of from about 5.4 to about 6.3;
(n) a level of protease activity of less than about 3 nKat/L;
(o) a level of prekallikrein activity of less than about 20 IU/mL;
(p) a tri (n-butyl) phosphate (TnBP) content of less than about 5 μg/mL; and
(q) a PS80 content of less than about 18 mg/mL.

### Claim 56

A composition comprising (i) a hemopexin content of from about 95 mg/mL to about 110 mg/mL, (ii) a hemopexin monomer content of at least about 99% of total protein, and (ii) a heme specific binding activity of at least about 97% of total protein.

### Claim 57 (depends on 56)

The composition of claim 56, further comprising (i) a transferrin content of less than about 0.25 mg/mL and (ii) a haptoglobin content of less than about 0.03 g/L haptoglobin.

### Claim 58 (depends on 56, 57)

The composition of claim 56 or claim 57, further comprising no detectable apolipoprtein A1 and/or albumin content.

### Claim 59 (depends on 56, 57)

The composition of claim 56 or claim 57, further comprising (i) an albumin content of less than about 0.009 mg/mL, and (ii) an Apo-A1 content of less than about 0.06 mg/mL.

### Claim 60 (depends on 56, 57, 58, 59)

The composition of any one of claims 56 to 59, further comprising comprises no detectable protease activity.

### Claim 61 (depends on 53, 54, 55, 56, 57, 58, 59, 60)

A formulation comprising the composition of any one of claims 53 to 60 and a pharmaceutically acceptable carrier.

### Claim 62 (depends on 61)

The formulation of claim 61, comprising about 15 mM citrate phosphate buffer, about 150 mM NaCl, a pH of about 7.2 and a concentration of hemopexin of about 100 mg/mL.

### Claim 63 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any one of claims 53 to 60 or the formulation of claim 61 or claim 62, wherein the composition or formulation is suitable for pharmaceutical administration after storage for 12 months at 2° C. to 8° C. and/or at ambient temperature.

### Claim 64 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of treating a condition associated with hemolysis, the method comprising administering to a subject in need thereof the composition of any one of claims 53 to 60 and 63, or the formulation of any one of claims 61 to 63.

### Claim 65 (depends on 64)

The method of claim 64, wherein the condition is an acute hemolytic condition or a chronic hemolytic condition.

### Claim 66 (depends on 65)

The method of claim 65, wherein the condition is selected from the group consisting of hemolytic anaemia, transfusion-induced hemolysis, hemolytic uraemic syndrome, an autoimmune disease, malaria infection, trauma, blood transfusion, open heart surgery using cardiopulmonary bypass and burns, hemoglobinemia and hemoglobinuria accompanied with hemolysis after burn.

### Claim 67 (depends on 65)

The method of claim 65, wherein the condition is selected from the group consisting of sickle cell anaemia, hereditary spherocytosis, hereditary elliptocytosis, thalassemia, congenital dyserythropoietic anemia and Paroxysmal nocturnal hemoglobinuria, systemic lupus erythematosus and chronic lymphocytic leukemia.

### Claim 68 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 63)

Use of the composition of any one of claims 53 to 60 and 63 in the manufacture of a medicament for treating a condition associated with hemolysis.

### Claim 69 (depends on 68)

The use of claim 68, wherein the condition is selected from the group consisting of hemolytic anaemia, transfusion-induced hemolysis, hemolytic uraemic syndrome, an autoimmune disease, malaria infection, trauma, blood transfusion, open heart surgery using cardiopulmonary bypass and burns, hemoglobinemia and hemoglobinuria accompanied with hemolysis after burn.

### Claim 70 (depends on 68)

The use of claim 68, wherein the condition is selected from the group consisting of sickle cell anaemia, hereditary spherocytosis, hereditary elliptocytosis, thalassemia, congenital dyserythropoietic anemia and Paroxysmal nocturnal hemoglobinuria, systemic lupus erythematosus and chronic lymphocytic leukemia.

### Claim 71 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The composition of any one of claims 53 to 60 and 63 or the formulation of any one of claims 61 to 63 for use in treating a condition associated with hemolysis.

### Claim 72 (depends on 71)

The composition for use according to claim 71, wherein the condition is selected from the group consisting of hemolytic anaemia, transfusion-induced hemolysis, hemolytic uraemic syndrome, an autoimmune disease, malaria infection, trauma, blood transfusion, open heart surgery using cardiopulmonary bypass and burns, hemoglobinemia and hemoglobinuria accompanied with hemolysis after burn.

### Claim 73 (depends on 71)

The composition for use according to claim 71, wherein the condition is selected from the group consisting of sickle cell anaemia, hereditary spherocytosis, hereditary elliptocytosis, thalassemia, congenital dyserythropoietic anemia and Paroxysmal nocturnal hemoglobinuria, systemic lupus erythematosus and chronic lymphocytic leukemia.
